Login to Your Account



Hualan moves into biosimilars with plans to start four MAbs trials

By Cornelia Zou
Staff Writer

Wednesday, November 12, 2014
HONG KONG – A Chinese vaccine and blood product maker is taking steps into the biosimilar market with four monoclonal antibody (MAbs) biosimilar drugs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription